• 대한방사성의약품학회지
• /
• 제2권1호
• /
• pp.1-2
• /
• 2016

• 대한방사성의약품학회지
• /
• 제5권1호
• /
• pp.1-2
• /
• 2019

• 대한방사성의약품학회지
• /
• 제4권2호
• /
• pp.43-44
• /
• 2018

• 대한방사성의약품학회지
• /
• 제5권2호
• /
• pp.69-70
• /
• 2019

• Journal of Radiation Protection and Research
• /
• 제37권4호
• /
• pp.231-236
• /
• 2012

This study derived measures to reduce exposure doses by identifying factors which affect the external radiation dose rate of patients treated with radiopharmaceuticals for PET-CT tests. The external radiation dose rates were measured on three parts of head, thorax and abdomen at a distance of 50cm from the surface of 60 PET-CT patients. It showed there are changes in factors affecting the external radiation dose rate over time after the administration of F-18 FDG. The external radiation dose rate was lower in the patients with more water intake than those with less water intake before the injection of radiopharmaceuticals at all three points: right after the injection of radiopharmaceuticals (average 4.17 mins), after the pre-PEET-CT urination step (average 77.47 mins), and right after the PET-CT test (average 114.15 mins). The study also found there is a need to increase the amount of water intake before the injection of radiopharmaceuticals in order to maintain a low external radiation dose rate in patients. This strategy is only possible under the assumption that the quality of the video has not changed after conducting this study on the relations between the image and quality. This study also found a need to use radiopharmaceuticals with the minimum amount needed for each patient because F-FDG doses affects the external radiation dose rate at the point right after the injection of radiopharmaceuticals. Urination frequency was the most significant factor to affect the external radiation dose rates at the point right after the PET-CT test and the point after the pre-PET-CT urination step. There is a need to realize the strategy to increase the urination frequency of patients to maintain the external radiation dose rate low (average 77.47 mins) before and after the injection of radiopharmaceuticals. In addition, at this point, there is a need to take advantage of personal strategies because the external radiation dose rate is lower if the fasting time is shorter, the contrast medium is used, and the amount of water intake is increased after the administration of radiopharmaceuticals. Finally this study found the need to be able to generalize these findings through an in-depth research on the factors affecting the external radiation dose rate, which includes radiopharmaceutical dose, urination frequency, the amount of water intake, fasting time and the use of contrast medium.

• 대한방사성의약품학회지
• /
• 제2권2호
• /
• pp.123-131
• /
• 2016

Increasing clinical demand for carbon-11 labeled radiopharmaceuticals has triggered technological advances in fields of radiochemistry and automated modules. Even though carbon-11 has a short half-life ($t_{1/2}=20.4min$), the consecutive second production of carbon-11 labeled radiopharmaceutical in one $^{11}C$-synthetic module should be delayed at least over 4 h to avoid the high radiation exposure. We herein aimed to produce two different carbon-11 labeled radiopharmaceuticals ([$^{11}C$]PIB and [$^{11}C$]methionine) by sharing of [$^{11}C$]methylation source in one $^{11}C$-synthetic module. The synthesis of $^{11}C$-labeling reagents ($[^{11}C]CH_3I$ or $[^{11}C]CH_3OTf$) is fully automated using the commercial TRACERlab $FX_{C-pro}$ module and is readily adaptable to $^{11}C$-labeling reactor for [$^{11}C$]PIB as well as another $^{11}C$-labeling apparatus for [$^{11}C$]methionine via the three-way valve. After completing the [$^{11}C$]PIB production, the re-synthesized $[^{11}C]CH_3I$ was passed through the three-way valve connected the polyetheretherketone (PEEK) line and loaded into the C18 Sep-Pak cartridge including the methionine precursor. The labeled product [^${11}C$]methionine was purified by a simple cartridge separation and reformulated into saline. The radiochemical yield of [$^{11}C$]PIB and [$^{11}C$]methionine were $5.3{\pm}0.6%$ and $18.7{\pm}0.8%$ (n.d.c.), respectively, with over 97% of radiochemical purity. The specific activity of [$^{11}C$]PIB was over $110GBq/{\mu}mol$. Total production time of two radiopharmaceuticals needs about 2 h from $1^{st}$ beam irradiation including quality control tests. Final [$^{11}C$]PIB and [$^{11}C$]methionine were satisfied all quality control test standards.

• 대한임상검사과학회지
• /
• 제53권1호
• /
• pp.1-10
• /
• 2021

방사성의약품은 방사선을 방출하는 방사성동위원소를 의약품에 표지하여 진단 및 치료 목적으로 사용하는 의약품이다. 방사성의약품은 제조 및 품질관리기준을 준수하여 제조해야 하며, 환자에게 투여되기 전 품질관리시험을 실시하여 안전성을 입증해야 한다. 방사성의약품의 품질관리는 시험의 특성에 따라 생물학적 시험과 물리화학적 시험으로 분류할 수 있다. 생물학적 시험에는 무균시험, 엔도톡신시험, 여과막 완전성 시험이 있으며, 물리화학적 시험에는 성상, 확인시험, 방사화학적 순도시험, 이핵종 시험, 화학적 순도시험, 잔류용매 시험, pH, 불용성이물시험, 함량 등이 있다. 주사제의 형태로 제조되는 방사성의약품은 무균상태이어야 하므로 제조 후 무균시험 및 여과막 완전성 시험을 수행하여 완제의약품의 무균성을 입증하며, 원자재 및 제조과정에서 혼입될 수 있는 발열성 물질은 환자의 생명에 위험을 줄 수 있으므로 엔도톡신시험을 실시하여 발열물질의 오염여부를 확인한다. 방사성의약품은 화학적 합성에 의해 제조되기 때문에 완제의약품 내 부산물 및 불순물의 혼입여부를 평가해야 한다. 제조된 방사성의약품의 성상 및 불용성이물을 육안으로 확인하며, 완제의약품 내 잔류할 수 있는 부산물 및 유기용매 등은 환자에게 유해할 수 있으므로 화학적순도, 잔류용매 및 pH를 평가한다. 그리고 방사성의약품으로부터 방출되는 방사선을 이용하여 반감기, 방사화학적 순도, 이핵종, 함량 등을 평가하여 목적하는 방사성동위원소가 기준에 적합하게 의약품에 표지되었는지를 확인한다. 특히, 방사성의약품은 일반의약품과 다르게 방사선 피폭의 위험성이 항상 존재하기 때문에 품질관리 시 검사시간을 줄이도록 노력해야 하며, 방사성물질에 오염되지 않게 주의를 기울여야 한다.

• 대한방사성의약품학회지
• /
• 제9권1호
• /
• pp.17-21
• /
• 2023

In this study, we evaluated the targeting of prostate cancer (PCa) using [¹⁸F]Florastamin in non-clinical study, for the purpose of therapeutic monitoring of [¹⁷⁷Lu]Ludotadipep, a therapeutic radiopharmaceutical for PCa, [¹⁸F]Florastamin/[¹⁷⁷Lu]Ludotadipep was co-administered to a single-individual prostate tumor bearing mouse model, mimicking clinical condition. Considering the difference in half-life of the two isotopes (¹⁸F or ¹⁷⁷Lu), image scan of whole-body autoradiography was performed at 24 or 48 h after preparation of frozen section, respectively. Then, it was confirmed whether they showed the same targeting efficiency for the area of tumor. A tumor xenograft model was prepared using PSMA-overexpressing PC3-PIP prostate cancer cells. [¹⁸F]Florastamin [111 MBq (3 mCi) in 100 µL]/¹⁷⁷Lu]Ludotadipep [3.7 MBq (100 µCi) in 100 µL] was co-administered through the tail vein, and 2 hours after administration, the mice were frozen, and after freezing for 24 hours, whole-body cryosection was performed at 24 h after freezing. Image scanning using cryosection was performed after 24 or 48 hours after freezing, respectively. In the scan image after 24 hours, tumor uptake of [¹⁸F] Florastamin/[¹⁷⁷Lu]Ludotadipep were simultaneously observed specific uptake in the tumor. In the scan image after 48 hours in the same section, signal of ¹⁸F was lost by decay of radioisotope, and specific uptake image for [¹⁷⁷Lu]Ludotadipep was observed in the tumor. Uptake of [¹⁷⁷Lu]Ludotadipep was specific to the same tumor region where [¹⁸F]Florastamin/[¹⁷⁷Lu]Ludotadipep was uptake. These results suggested that [¹⁸F]Florastamin showed the same tumor uptake efficiency to PCa as [¹⁷⁷Lu]Ludotadipep, and effective therapeutic monitoring is expected to be enable using [¹⁸F]Florastamin during [¹⁷⁷Lu]Ludotadipep therapy for PCa.

• 대한핵의학회지
• /
• 제4권1호
• /
• pp.51-60
• /
• 1970

1969년도 일년간 당연구실에서 합성한 방사성의약품의 양은 131mc이며 그 종류는 $Hippuran-^{131}I$의 4종에 달하였다. 이들 의약품의 품질 및 안정도를 Paper partition chromatography 및 thin-layer chromatography를 이용하여 시험하고 그 결과를 외국제품의 품질 및 안정도와 비교 검토하여 보았다. 그 결과 합성방식에 따라 품질에 차이가 있었다. 본 연구소제품이 품질 및 안정도면에서 우수하였다. 본 연구에서는 방사성의약품을 임상에 사용하는데 주의해야 할 품질관리 및 안정도 test에 관하여 그 시험방법을 아울러 기술하였다.

• 대한방사성의약품학회지
• /
• 제1권2호
• /
• pp.109-117
• /
• 2015

Radiation synovectomy has been proposed as a promising palliative therapy for recurrent joint effusions for the last two or three decades. Ionizing radiations emitted by intrarticularly administered radiolabelled colloids. The aim of this study was to assess the effectiveness of radiation synovectomy (RSV) using $^{188}Re$-tin colloid in the treatment of recurrent joint effusions and chronic synovitis of knee joints. Three phase bone scan was acquired for the concerned joint prior to radiosynovectomy. $^{188}Re$-tin colloid was prepared as per the reported protocol. 9 patients, diagnosed with rheumatoid arthritis and suffering from chronic resistant synovitis of the knee, ankle or elbow joints were administered the radiopharmaceuticals, checked for radiochemical purity >95% by intraarticular route. A whole body scan was acquired 2 h post-radiosynovectomy. In all the 9 treatments, no leakage to non-target organs was visible in the whole body scan. Static scans of the joint revealed complete retention of $^{188}Re$-tin colloid in the joints post administration of the agent. Clinically all patients exhibited a complete or partial response. RSV with $^{188}Re$-tin colloid was safe and effective in patients with chronic synovitis of rheumatoid origin.